StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson REMICADE (infliximab) — Worldwide sales by Year

REMICADE (infliximab) — Worldwide sales ($M) ($M)

Johnson & Johnson REMICADE (infliximab) — Worldwide sales: $1,768M in FY2025, up 10.2% from a year earlier.

Latest, FY2025
1,768
Period ended Dec 28, 2025
Change on a year earlier
+10.2%
1,605 in FY2024
History
10 years
Since FY2016
Sources
7
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-11) ↗

Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedREMICADE (infliximab) — Worldwide sales ($M) ($M)Year on yearSource
FY2025Dec 28, 20251,768+10.2%Form 10-K (filed 2026-02-11) ↗
FY2024Dec 29, 20241,605-12.7%Form 10-K (filed 2026-02-11) ↗
FY2023Dec 31, 20231,839-21.5%Form 10-K (filed 2026-02-11) ↗
FY2022Jan 1, 20232,343-26.6%Form 10-K (filed 2025-02-13) ↗
FY2021Jan 2, 20223,190-14.9%Form 10-K (filed 2024-02-16) ↗
FY2020Jan 3, 20213,747-14.5%Form 10-K (filed 2023-02-16) ↗
FY2019Dec 29, 20194,380-17.8%Form 10-K (filed 2022-02-17) ↗
FY2018Dec 30, 20185,326-15.7%Form 10-K (filed 2021-02-22) ↗
FY2017Dec 31, 20176,315-9.3%Form 10-K (filed 2019-02-20) ↗
FY2016Jan 1, 20176,966–Form 10-K (filed 2019-02-20) ↗

Breakdown

What makes up REMICADE (infliximab) — Worldwide sales

Cite this data

StockData. (2026). Johnson & Johnson REMICADE (infliximab) — Worldwide sales ($M), annual FY2016–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-remicade

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.